Gentian Diagnostics (GENT) Stock Overview
Develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
GENT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Gentian Diagnostics ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 55.60 |
| 52 Week High | NOK 65.80 |
| 52 Week Low | NOK 37.00 |
| Beta | 0.39 |
| 1 Month Change | 0.72% |
| 3 Month Change | -2.11% |
| 1 Year Change | 34.95% |
| 3 Year Change | 47.48% |
| 5 Year Change | -9.59% |
| Change since IPO | 113.85% |
Recent News & Updates
Recent updates
Gentian Diagnostics' (OB:GENT) Performance Raises Some Questions
Oct 31
Market Participants Recognise Gentian Diagnostics ASA's (OB:GENT) Revenues Pushing Shares 27% Higher
May 09Why Gentian Diagnostics' (OB:GENT) Earnings Are Weaker Than They Seem
Feb 20
Launching NT-proBNP Test And Expanding Partnerships Will Broaden Cardiology Portfolio
Strategic partnerships and continual global expansion enhance Gentian's market presence and drive revenue growth.Gentian Diagnostics ASA's (OB:GENT) P/S Is Still On The Mark Following 25% Share Price Bounce
Feb 07Investors Appear Satisfied With Gentian Diagnostics ASA's (OB:GENT) Prospects As Shares Rocket 33%
Jun 29Analyst Estimates: Here's What Brokers Think Of Gentian Diagnostics ASA (OB:GENT) After Its Annual Report
Feb 14Here's Why We're Not At All Concerned With Gentian Diagnostics' (OB:GENT) Cash Burn Situation
Oct 28We're Not Worried About Gentian Diagnostics' (OB:GENT) Cash Burn
May 11Can You Imagine How Gentian Diagnostics' (OB:GENT) Shareholders Feel About The 57% Share Price Increase?
Mar 20What Percentage Of Gentian Diagnostics AS (OB:GENT) Shares Do Insiders Own?
Feb 21Have Insiders Been Selling Gentian Diagnostics AS (OB:GENT) Shares?
Jan 17
Gentian Diagnostics AS (OB:GENT): When Will It Breakeven?
Dec 14Shareholder Returns
| GENT | NO Medical Equipment | NO Market | |
|---|---|---|---|
| 7D | 0.7% | 1.6% | 0.5% |
| 1Y | 35.0% | 0.9% | 5.4% |
Return vs Industry: GENT exceeded the Norwegian Medical Equipment industry which returned 0.9% over the past year.
Return vs Market: GENT exceeded the Norwegian Market which returned 5.4% over the past year.
Price Volatility
| GENT volatility | |
|---|---|
| GENT Average Weekly Movement | 4.3% |
| Medical Equipment Industry Average Movement | 5.6% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in NO Market | 10.3% |
| 10% least volatile stocks in NO Market | 2.5% |
Stable Share Price: GENT has not had significant price volatility in the past 3 months compared to the Norwegian market.
Volatility Over Time: GENT's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 63 | Matti Heinonen | www.gentian.com |
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. It also develops NT-proBNP Immunoassay, an aid in the diagnosis, monitoring, and assessment of severity in individuals suspected of having congestive heart failure, which is in product development phase.
Gentian Diagnostics ASA Fundamentals Summary
| GENT fundamental statistics | |
|---|---|
| Market cap | NOK 857.48m |
| Earnings (TTM) | NOK 42.78m |
| Revenue (TTM) | NOK 172.52m |
Is GENT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GENT income statement (TTM) | |
|---|---|
| Revenue | NOK 172.52m |
| Cost of Revenue | NOK 77.53m |
| Gross Profit | NOK 94.99m |
| Other Expenses | NOK 52.21m |
| Earnings | NOK 42.78m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 11, 2026
| Earnings per share (EPS) | 2.77 |
| Gross Margin | 55.06% |
| Net Profit Margin | 24.80% |
| Debt/Equity Ratio | 0% |
How did GENT perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/17 22:50 |
| End of Day Share Price | 2025/11/17 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gentian Diagnostics ASA is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Martinsson | DNB Carnegie |
| Geir Holom | DNB Carnegie |